Hinge Health Inc. Class A Common Stock vs S&P Global Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while S&P Global Inc trades at $408.03 (market cap $120.87B). The key difference: S&P Global Inc is far larger — about 14.3× Hinge Health Inc. Class A Common Stock's market cap, and S&P Global Inc pays a 0.95% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and S&P Global Inc for 124 Days on average.
| HNGE | SPGI | |
|---|---|---|
Market Cap | $8.48B | $120.87B |
Volume | 879,799 | 1,391,754 |
Sector | Health | Financials |
52-Week High | $105.14 | $517.92 |
52-Week Low | $31.17 | $370.42 |
Typical Hold Time | 0 Days | 124 Days |
Enterprise Value | $8.10B | $132.35B |
Dividend Yield | — | 0.95% |
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
S&P Global (SPGI) trades at $408.57, down 0.88% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong fundamentals with Q1 and Q2 2026 earnings beats, revenue growth to $15.34B in 2025, and robust profitability margins. Recent news highlights expansion into digital asset risk assessment and AI-driven growth initiatives.
Outlook remains positive with an 85.7% analyst buy rating and a $509.50 consensus price target, implying significant upside. Key risks include execution of acquisitions and macroeconomic sensitivity, but the firm's entrenched market position and cash flow stability support a favorable investment case for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →